Clinical trial
Comparing Weight Gain on F/TAF and Placebo Using DISCOVER and iPrEx Study Data
Austria
Brazil
Canada
Denmark
Ecuador
France
Germany
Ireland
Italy
Netherlands
Peru
South Africa
Spain
Thailand
United Kingdom
United States
EU PAS number:
EUPAS1000000509
First published:
08/04/2025
StudyPlanned
Comparative Effectiveness of Sotorasib Versus Docetaxel Monotherapy in Second Line and Beyond (2L+) Among Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in the Cancer Analysis System Database in England (20240164)
United Kingdom
EU PAS number:
EUPAS1000000405
First published:
16/04/2025
StudyOngoing
Matching-Adjusted Indirect Treatment Comparison of Sotorasib vs Adagrasib for Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (20240246)
Australia
Austria
Belgium
Brazil
Canada
Denmark
Finland
France
Germany
Greece
Hong Kong
Hungary
Ireland
Italy
Japan
Korea, Republic of
Netherlands
Poland
Portugal
Puerto Rico
Romania
Russian Federation
Singapore
Spain
Sweden
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS1000000380
First published:
03/12/2024
StudyOngoing
Machine learning prediction of anemia events before and after talazoparib dose modification using TALAPRO-2 phase 3 trial data
United States
EU PAS number:
EUPAS1000000344
First published:
09/07/2025
StudyOngoing
Effectiveness of inhaled treprostinil versus standard of care for the treatment of pulmonary hypertension associated with interstitial lung disease: A propensity score-weighted study of the INCREASE trial and registry data from Europe
Austria
Belgium
Germany
Greece
Hungary
Italy
Latvia
Lithuania
Netherlands
Slovakia
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS1000000238
First published:
10/09/2024
StudyPlanned
Meta-analysis to assess cardiovascular safety of mavacamten (CV027-1148)
Australia
Austria
Belgium
Brazil
Canada
Chile
China
Denmark
Finland
France
Germany
Greece
Hungary
India
Israel
Italy
Japan
Korea, Democratic People's Republic of
Netherlands
Norway
Poland
Portugal
Spain
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS1000000234
First published:
05/07/2024
StudyPlanned
Shortening the time to confirm or to rebut Adverse events of interest related to innovative Therapies for immune-mediated inflammATory dIseases: cross-talking between different data sOURces. SATURATIOn study.
France
EU PAS number:
EUPAS1000000207
First published:
27/06/2024
StudyPlanned
Real-World Comparative Effectiveness Study of TYVASO (Inhaled Treprostinil) in the Treatment of PH-ILD
Germany
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000109
First published:
23/07/2024
StudyOngoing